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Rochelle Chashmi Ratnayake 
DIFFERENTIAL RECRUITMENT OF HOST PROTEINS TO THE COXIELLA BURNETII VACUOLE 
IN THE ABSENCE OF THE STEROL REDUCTASE CBU1206 
Q fever is a heavily underdiagnosed and underreported infection caused by the 
obligate intracellular pathogen Coxiella burnetii. Following entry into the host cell, 
Coxiella replicates in the acidic phagolysosome-like parasitophorous vacuole termed the 
Coxiella Containing Vacuole (CCV). The CCV is a large and highly fusogenic compartment 
that actively fuses with the host endocytic pathway during maturation of the 
phagolysosome. Evidence suggests that the development of the CCV is sensitive to 
increasing cholesterol levels and leads to CCV acidification and bacterial death. 
Therefore, we hypothesize that CCV cholesterol concentration is carefully modulated 
through the Coxiella encoded sterol reductases (CBU1206 and CBU1158). A ∆CBU1206 
mutant of Coxiella is hypersensitive to cholesterol and displays growth defects in 
intracellular replication and CCV development.  
Following fusion with the host endocytic pathway, the Coxiella NMII Phase II 
(WT) CCVs readily acquire host proteins such as LAMP1, CD63, Rab7, ORP1L, RILP, and 
LC3. These heterotypic events with the host endosomal cascade are presumed to 
provide selected subsets of endocytosed cargo and membrane. Therefore, I investigated 
whether ΔCBU1206 CCV heterotypic fusion events are defective due to altered lipid 
content on the CCV membrane.  
I observed increased accumulation of sterols on the ΔCBU1206 CCV membrane. 
Similar to WT, the mutant readily fuses host lysosomes and readily acquires the host 
glycoprotein LAMP1 but displays reduced localization of CD63 (LAMP3). Additionally, 
reduced localization of the late endosomal markers Rab7, ORP1L, and RILP was 
observed suggesting that late endosome fusion maybe defective in ΔCBU1206. Further, 
reduced localization of LC3 was also observed suggesting that the mutant may also be 
defective in fusing with autophagosomes. Finally, the mutant possesses a functional 
Type 4 Secretion System that secretes a moderate amount of effector proteins relative 
to WT. Considering the vast array of functions accomplished by the effectors secreted, 
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the moderate effector secretion by the mutant could influence the endocytic pathway 
fusion processes as well as CCV development. Collectively, this body of work suggests 
that the lack of sterol reductase CBU1206 in Coxiella results in defective heterotypic 
fusion events of the CCV membrane that could alter pathogenesis and CCV expansion.  
 
Stacey Gilk, Ph.D., Chair 
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INTRODUCTION 
History of Q Fever 
In 1935, an outbreak of a mysterious undiagnosed febrile illness occurred among 
slaughterhouse workers in Brisbane, Australia. One year later, Herald Rea Cox and 
Gordon Davis of the Rocky Mountain Laboratory unknowingly isolated the same 
infectious agent from ticks near Nine Mile Creek in Missoula, Montana [1].  They 
described it as a “filter-passing” microorganism and called it Rickettsia diaporica.  
At the time, the causative agent and the disease were not well characterized and 
was termed “Query” fever and is now commonly referred to as “Q fever”. Continuing to 
investigate the mysterious illness, Edward Holbrook Derrick, the Director of the 
Laboratory of Microbiology and Pathology in the Queensland Health Department at 
Brisbane, attempted to isolate the agent of disease [2]. He induced the illness in guinea 
pigs but was unable to isolate the bacterium and suspected the culprit to be a virus. 
Although this initial attempt at isolating the pathogen was unsuccessful it was later 
reattempted by Frank Macfarlene Burnet and Mavis Freeman who were successful at 
isolating the bacterium from patients [3]. Their work on the spleen sections of infected 
mice used the Giemsa method to visualize miniature rods. Taking into account the small 
size of the rods and the vacuoles that were different from any known type of Rickettsia, 
the authors concluded that they were observing a new type of Rickettsia and named it 
Rickettsia burnetii [4]. In 1938, the first reported laboratory-acquired Q fever case 
occurred in Rolla Eugene Dyer, the Director of the National Institutes of Health [2]. Thus, 
the link between the Nine Mile agent from Montana and the Australian agent of Q fever 
was established when cross-immunity was demonstrated between the two. Once the 
causative agent was definitively established and the pathogen was discovered to be 
significantly different from other organisms in the Rickettsia genus; the pathogen was 
renamed Coxiella burnetii to acknowledge both research groups [5] 
Coxiella Infection in Mammals  
C. burnetii is commonly found in goat, sheep,  and cattle reservoirs but has been 
confirmed in marine mammals, reptiles, and birds [6]. Most infections in animals are 
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asymptomatic and causes reproductive disorders ranging from abortion, endometritis, 
low birth weight, and infertility. The main route of C. burnetii transmission is by inhaling 
aerosols contaminated with the organisms and these aerosols are frequently shed from 
infected animals [7]. Shedding primarily occurs through birth products, milk, urine, and 
feces of infected animals; however, animals have seroconverted after exposure to C. 
burnetii without any active shedding of organisms. Humans tend to acquire the infection 
by inhaling contaminated aerosols and consumption of contaminated raw milk and dairy 
products. The pathogen preferentially infects cell types that rapidly internalize 
pathogens such as mononuclear phagocytes and macrophages [8].  Symptoms of C. 
burnetii  infection include fever, fatigue, chills, and myalgia occur following an 
incubation period of 2 to 3 weeks [7] [6].  
Approximately 60% of the infections are reported to be asymptomatic while the 
remaining patients acquire acute Q fever that manifests through an influenza-like 
illness, atypical pneumonia or hepatitis [9]. While only 1% to 5% of Q fever cases 
progress to chronic infection, these cases can result in fatal endocarditis that can occur 
months to years following acute infection. Chronic Q fever can also result in chronic 
fatigue syndrome characterized by myalgia, night sweats, arthralgia, night sweats, and 
changes in moods. In pregnant women Q fever has been shown to cause placentitis, 
abortion, low birth weight, premature birth, and consequently neonatal death [10]. 
Similar to reports of other mammals infected with C. burnetii, pregnant women with Q 
fever suffer from bacterial colonization that can occur in the uterus, placenta or 
mammary glands. Chronic complications such as these tend to occur if the woman is 
pregnant at the time of primary infection [9]. 
The largest C. burnetii outbreak to date occurred in the Netherlands where there 
were 4000 human cases between 2007 and 2009. There were a series of community 
outbreaks that occurred in the south-eastern provinces of the Netherlands and goats 
were identified as the primary source of the animal outbreaks. During the epidemic 28 
dairy goat farms and 2 dairy sheep farms reported abortion percentages upwards of 
60% [11]. 
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The Bacterium 
C. burnetii is a pleomorphic Gram-negative coccobacillus 0.2 to 0.4 μm and 
approximately 1 μm  long but not stainable with the Gram technique [12]. The 
bacterium is known to double every 20 and 45 h inside cells where it forms a vacuole 
that progressively acquires phagolysosome-like characteristics. C. burnetii is the only 
bacterial pathogen that actively replicates inside a phagolysosome-like vacuole, which is 
known as the Coxiella Containing Vacuole (CCV). The vacuole is characterized by its 
acidic pH, cationic peptides and acidic hydrolases [13]. Coxiella is able to transition 
between two cell variants: the large-cell variant (LCV) and the small-cell variant (SCV). 
The LCV is metabolically active while the SCV is environmentally stable. SCVs are smaller 
rods approximately 0.5 μm in size and are characterized by a condensed cytoplasm and 
condensed chromatin. This environmentally stable cell variant form is resistant to 
sonication, heat shock, osmotic shock, oxidative stress, and pressure. This form is also 
known to express Hq1 and ScvA, basic peptides that are predicted to function in DNA 
binding during periods of extended dormancy [14, 15]. In contrast, LCVS are the 
replicative form that is typically larger than 0.5 μm and contain dispersed chromatin 
[12]. Translation machinery of the bacteria such as elongation factor Ts (EF-Ts) and 
elongation factor Tu (EF-Tu) were shown to be upregulated in LCVs and not in SCVs [16]. 
The transition of the bacteria from SCV to LCV is thought to occur approximately 8 hours 
post infection (hpi) but the CCV is predominantly LCVs later on in the infection around 2 
to 6 days post infection [17]. These differences between the SCV and LCV forms indicate 
the biphasic development cycle of C. burnetii and the differential regulation involved.  
The Host Endocytic Pathway 
The C. burnetii CCV is highly fusogenic and acquires cellular markers through 
heterotypic fusion events with the host endocytic pathway. Host endocytosis begins 
with the formation of vesicles through membrane fission events. These vesicles termed 
early endosomes contain endocytosed material such as membrane components, 
macromolecules, particles, and fluid solutes [18, 19] (Figure 1). The pH of the early 
endosome (~6.2) is achieved through the V-ATPase proton pump. Maturation of the 
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host early endosome to the late endosome with a pH of approximately 5.5 is mediated 
by GAPs (GTPase-activating proteins) and GEFs (guanine nucleotide exchange factors) 
that act on Rabs [20]. GTPases are critical membrane-associated proteins that function 
as regulators of vesicular trafficking pathways; they are commonly referred to as the 
Rab family. Rab5 is localized to early endosomes (EEs) through the GTP effector 
Rabaptin 5 that generates a positive feedback loop [21]. The conversion of Rab5 to Rab7 
along with the loss of Early Endosome Antigen 1 (EEA1) drives the maturation of the EE 
to the late endosome (Figure 2). The late endosome is a multivesicular body that then 
fuses with lysosomes that have a pH of approximately 4.5 [20]. EEs have been shown to 
function as nutrient sensing organelles that also mediate the starvation response and 
regulates energy metabolism. In addition, autophagosomes are formed with the aid of 
Atg (autophagy related gene) proteins such as LC3 and LC3-II - its modified form. The 
autophagosomes then fuse with lysosomes until they are digested by lysosomal 
proteases to be used by the cell [22]. The motility of late autophagosomes and late 
endosomes on microtubules is mediated by Rab7, RILP, and ORP1L [18]. The host 
endocytic pathway concludes with the formation of mature acidic lysosomes containing 
the glycoprotein LAMP1. It is a common marker for lysosomes, however, LAMP-1 
labeled vesicles are heterogeneous [23]. The mature CCV acquires these cellular 
markers and remains around pH ~5.2 [24].  
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Figure 1. The Host Endocytic Pathway. The endocytic pathway begins when membrane 
fission events produce vesicles termed early endosomes that accumulate cargo such as 
macromolecules and membrane components. The early endosomes mature into late 
endosomes by conversion on Rab5 to Rab7. Early endosomes containing Rab5 and late 
endosomes containing Rab7 mediate exchange and transport of compartments with the 
trans-Golgi network (TGN). These vesicle populations carry a specific subset of 
endocytosed cargo and remain around pH 6.0 to 5.5. They mature through homotypic 
fusion events and generate the classical lysosome containing lysosomal +++hydrolases 
and pH 4.5. 
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Figure 2. Rab5 to Rab7 Conversion. Early endosomes contain the GTPase Rab5 that 
distinguishes it from the late endosomes. Rab5 is found on early endosomes forming a 
complex with Rabex-5, a GEF, and effector Rabaptin 5. The conversion of Rab5 to Rab7 
is mediated by GAPs and GEFs that facilitate the GTP hydrolysis events. Rab5 is then 
replaced with Rab7 on late endosomes. Recruitment of the Rab7 GTPase occurs through 
the protein Mon1-Ccz1 that acts as a GEF and allows for the maturation of the early 
endosome to the late endosome. 
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C. burnetii Life Cycle 
The C. burnetii life cycle within host cells is well characterized and it has been 
established that entry into a host cell is a phagocytic event and occurs through host cell 
receptors: CR3 (complement receptor-3), CD47 (integrin-associated protein) and αvβ3 
integrin [10, 25]. Following internalization into the host cell, unlike most intracellular 
pathogens Coxiella actively fuses with the host endosomal cascade and does not avoid 
fusion with lysosomes (Figure 3). The nascent CCV fuses with the endosomal cascade 
and recruits Rab5, mannose receptors, and Rab7 approximately 40 minutes post-
infection [26].  The CCV then begins to acidify and this is thought to occur by acquiring 
its lysosomal characteristics, acidic pH, and lysosomal membrane by fusion with host 
lysosomes. It acquires LAMP-1 (Lysosome-associated membrane glycoprotein-1) and 
other glycoproteins such as LAMP-2 and LAMP-3 (commonly referred to as CD63) [24, 
26].  These fusion events with the host lysosomes have been reported to occur 2 to 6 
hours post infection and results in the recruitment of lysosomal enzymes such as acid 
phosphatases, hydrolases, and cathepsin D [13, 24]. 
These events increase the metabolic activity of Coxiella and establishes an acidic 
pH within the CCV that upregulates expression of the Dot/Icm type IV secretion system 
(T4SS)[27]. The T4SS is a pilus-like structure that spans the inner and outer bacterial 
membranes forming a translocation pore in the CCV membrane through which Coxiella 
delivers approximately 130 effector proteins to manipulate host cell processes, initiate 
intracellular replication and promote CCV expansion [27, 28].  
The phagosome maturation process continues while Coxiella actively fuses with 
the host endocytic pathway. This then results in the late phagosome that acquires 
endocytic SNARE proteins such as syntaxin-17 and Vamp7 that have been shown to 
mediate homotypic fusion events of Coxiella phagosomes [29]. Approximately 48 hours 
post infection the CCV begins to recruit autophagy proteins such as microtubule-
associate protein 1A/1B  light-chain 3 (LC3), p62, and Beclin through PV and mature 
autophagosome interactions [30, 31]. Although the mature CCV has been shown to be 
negative for the presence of EE markers such as EEA1, mutants of Coxiella proteins that 
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target the CCV membrane exhibit fatal defects in CCV formation and intracellular 
replication [32] [33]. These findings indicate that the both host and bacterial protein 
localization on the CCV membrane are required to maintain steady CCV biogenesis and 
intracellular growth.  
The host cell remains viable despite the expansion of the CCV and this could be 
attributed to the anti-apoptotic activity and activation of pro-survival factors by C. 
burnetii [34]. The survival of infected cells may be critical for the spread and 
maintenance of both acute and chronic infections in mammals.  
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Figure 3. Coxiella Fusion with the Host Endocytic Pathway. Coxiella burnetii is endocytosed by binding to host adhesion receptor αvβ3 
integrin. The early phagosome fuses matures by fusing with early endosomes and autophagosomes while acquiring cellular markers 
such as Rab5 and LC3. The early phagosome then matures with the more acidic vesicles such as late endosomes and acquires markers 
such as ORP1L, Rab7, RILP and CD63. The maturation process continues as the Coxiella phagosome fuses with host lysosomes. At this 
stage the phagosome matures into a phagolysosome where it acquires lysosome specific components such as hydrolases and the 
LAMP1. 
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Cholesterol and Coxiella Pathogenesis 
Cholesterol has been implicated in important roles for host-pathogen 
interactions and has been recognized as a critical structure in pathogen-occupying 
vesicles [35]. Obligate intracellular pathogens such as C. burnetii are dependent on the 
host cell for substantial amounts of the growth requirements and therefore, they have 
evolved intricate mechanisms to obtain vital nutrients [36]. They can then manipulate 
the cholesterol trafficking pathways inside the host cells to acquire host nutrients and 
maintain the intracellular niche [37]. These processes are predicted to occur by hijacking 
cholesterol uptake, metabolism, and storage [36].  
Coxiella has been shown to have a sterol rich CCV membrane decorated with 
lipid raft proteins flotillin-1 and flotillin-2 [38, 39]. The presence of lipid raft proteins and 
the mechanically strong structure of CCV membrane suggests that cholesterol may play 
a role in the CCV structural integrity [39]. Interestingly, the pathogen encodes a putative 
Δ24 sterol reductase homolog  CBU1206; this enzyme is absent in other prokaryotes 
[40]. The mammalian homolog of the Δ24 sterol reductase is DHCR24, which is 
responsible for catalyzing the final step in cholesterol biosynthesis by reducing sterol 
double bonds [39]. Previous studies demonstrate that the C. burnetii CBU1206 is able to 
reduce the C24 double bond of the ergosterol precursor in a Saccharomyces cerevisiae  
model [40]. The ability of CBU1206 to modify the yeast sterol precursor indicates that it 
is an active enzyme that might serve a critical function in modifying sterols. Since 
Coxiella infects mammalian cells that maintain cholesterol as the central lipid for cellular 
lipid homeostasis, it is unlikely that CBU1206 is used for producing cholesterol [41]. It 
has been shown that high levels of cholesterol leads to over-acidification of the CCV, 
defective fusion with the host endocytic pathway, and bacterial death [42]. Predicted 
functions of CBU1206 include conversion of cholesterol precursors to novel sterols or 
modification of cholesterol to a sterol more beneficial to C. burnetii. 
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Research Goals  
Building upon previous work indicating that increasing cholesterol 
concentrations are bacteriolytic to C. burnetii. We hypothesize that CCV cholesterol 
concentration is meticulously regulated through the Coxiella sterol reductase CBU1206. 
In order to better understand the mechanisms of CBU1206, the effects of altered lipid 
content on the CCV membrane and heterotypic fusion events; I observed the 
localization of host proteins by investigating a complete knockout mutant of the Coxiella 
Δ24 sterol reductase CBU1206 (∆CBU1206).  
Firstly, the effects of sterol deregulation on heterotypic fusion events with the 
∆CBU1206 CCV were investigated. The sterol deregulation effects were observed by 
scoring the localization of endolysosomal host proteins such as CD63, LAMP1, Rab7, 
ORP1L, RILP, and LC3 on the mutant CCV membrane as WT CCVs readily acquire proteins 
during infection. These fusion events are essential for maintaining an acidic and 
expanding vacuole that leads to disease. Our aim in investigating the localization of 
these cellular markers to the CCV membrane is to gain a deeper understanding of the 
relevance of these host proteins to the developing CCV. I expect to see reduced or 
heavily increased localization of both late endosome and lysosome markers due to the 
mutant having to compensate for the lack of a sterol reductase enzyme through 
currently unknown mechanisms.         
Secondly, the functional capacity of the Δ24 sterol reductase mutant Type 4 
Secretion System (T4SS) will be determined. The secretion system is a critical virulence 
factor that facilitates the secretion of approximately 130 effector proteins. These 
effectors regulate numerous aspects of the host cell to manipulate the host defense in 
response to Coxiella infection. These modulations of the host cell allow for a replication-
permissive vacuole that results in disease progression. The extent of effector secretion 
through the T4SS will be measured through a CyaA Reporter Assay that measures 
secretion efficacy through adenosine triphosphate (ATP) conversion to Cyclic AMP 
(cAMP). I expect to see a moderately functional T4SS for the mutant indicating that the 
phenotypes observed with the mutant CCV cannot be solely due to lack of effector 
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proteins but also because of aberrations in sterol regulation. Overall, these two aims 
allow us to further understand the function and importance of the Coxiella sterol 
reductases while illuminating potential therapeutic targets. 
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MATERIALS AND METHODS  
Bacterial Strains    
C. burnetii NMII Phase II (NMII, RSA439), C. burnetii ∆CBU1206 (NMII; clone 
41), ∆dotA mutant (2) and mCherry expressing strains were grown for 8 days in 1X 
ACCM-D media and washed twice with 1X PBS as described in (Omsland et al., 2009). 
For all experiments counting the presence of host proteins on the C. burnetii CCV, all 
strains were grown for 8 days in ACCM-D (nutritionally defined medium with known 
amino acid concentrations) (Sandoz et al., 2016) and washed twice with 1X PBS as 
described in (Omsland et al., 2009). The multiplicity of infection (MOI) was optimized for 
the (WT) C. burnetii NMII Phase II, and ∆CBU1206 for ~1 internalized bacterium per 
cell.   
Mammalian Cell Culture  
HeLa cells and Murine alveolar macrophages (MH-S cells) were maintained in 
RPMI (Roswell Park Memorial Institute medium) 1640 medium (Corning, New York, NY, 
USA)  that contained 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA, 
USA), and glutamine (Gibco, Paisley, Scotland, UK)  37°C and 5% CO2.  
Filipin Staining for Sterol Quantification 
On a 6 well-plate 5 x 104 cells per well of HeLa cells were plated and infected the 
following day. C. burnetii NMII Phase II and ∆CBU1206 were used to infect cells in 500 uL 
of RPMI 1640 medium at an optimal MOI. At 3 dpi cells were incubated with 5uM of 
U18666A (Fisher Scientific, Hanover Park, IL, US) for 4 hours at 37°C. These cells were 
then washed and fixed with 2.5% paraformaldehyde (PFA) (Alfa Aesar, Haverhill, MA, 
USA) for 15 mins and incubated with filipin at (1:100) (NC9384284; Fisher Scientific, 
Hanover Park, IL, US) for 1 hour in the dark. The cells were washed and mounted on 
slides with ProLong-Gold (Invitrogen).  
Transfection with GFP Plasmids   
5 x 104 cells per well of HeLa cells were seeded in a 24 plate in RPMI 1640 
medium. They were transfected with pEGFP plasmids containing Fugene 6 (Promega, 
Madison, WI, USA), according to manufacturer’s protocol. pEGFP plasmids encoding full-
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length ORP1L, Rab7, RILP, and LC3 were transfected. Approximately 48 hrs post-
transfection, the HeLa cells were infected with C. burnetii in 0.25 mL of 10% RPMI and 
incubated for 2 hours at 37°C, 5% CO2. The cells were then washed extensively with 1X 
PBS and incubated in 10% RPMI. At 0, 4, 12, 24, 48 and 72 hours post infection, the 
coverslips were fixed with 2.5% PFA for 15 minutes. The cells were then blocked and 
permeabilized for 20 minutes with 0.1% saponin and 1% bovine serum albumin (BSA).   
C. burnetii Recruitment of Host Proteins by Immunofluorescence Assay   
HeLa cells were plated at (2 x 105 cells per well of a 6-well plate for 0 and 
4 hr) and (5 x 104 cells per well of a 24 plate for 12, 24, 48 and 72 hours) and allowed to 
adhere overnight. For immunofluorescent labeling, HeLa cells were infected 
with mCherry C. burnetii NMII Phase II (WT) or mCherry ∆CBU1206, washed extensively 
with PBS, and incubated in 10% RPMI. At the indicated times post infection, infected 
cells were fixed with 2.5%  PFA for 15 minutes.  The cells were incubated with 
monoclonal antibodies mouse anti-CD63 (1:1000) (556019; BD Biosciences, San Jose, 
CA, USA), anti-LAMP1(1:1000) (ab24170; Abcam, Cambridge, MA, USA) and guinea pig 
anti-Coxiella serum (Coleman et al., 2007) for 1 h in 0.1% saponin BSA-PBS. The 
coverslips were then incubated with AlexFluor secondary antibodies (Invitrogen, 
Carlsbad, CA, USA) in 0.1% saponin BSA-PBS. The coverslips were mounted 
using ProLong-Gold plus 4′,6′-diamidino-2-phenylindole DAPI (Invitrogen) 
and visualized.      
Microscopy  
Immunofluorescent images were obtained using a Leica inverted microscope 
DMI6000B. Images were obtained using the a (63 x oil immersion objective) and at least 
20 CCVs were visualized for each condition during three biological replicate 
experiments. The CCVs were scored for the presence or absence of each of these host 
proteins (CD63, LAMP1, ORP1L, Rab7, RILP and LC3). All images were analyzed using the 
FIJI ImageJ software (written by Wayne Rasband at the US National Institutes of 
Health).    
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CyaA Translocation Assay   
C. burnetii cultures grown in ACCM- 2 was spun down at 16000xg for 15 min and 
suspended in 10% glycerol. Ten micrograms of PJB-CAT-CyaA or PJB-CAT-CyaA-
CvpA DNA was mixed with 50 uL of C. burnetii in a cold electroporation cuvette. The 
bacteria were electroporated at 1.8 kv, 500 ohms, at 25 microF and suspended in 
950 μL of pre-cooled RPMI prior to culturing in ACCM-2. The WT cultures were then 
treated with 3 μg/ml of Chloramphenicol while the ∆CBU1206 cultures received 3 μg/ml 
of Chloramphenicol and 3.5 μg/ml of Kanamycin. Chloramphenicol was used as a 
gene to confer resistance following transformation while Kanamycin was used to ensure 
Coxiella mutant status.    
Six strains were generated where WT, ∆CBU1206, and dotA C. burnetii were 
transformed with either pJB-CAT:CyaA:CvpA or pJB-CAT:CyaA only. The expression 
of CyaA was verified by Western blot using a Cya-3D1 primary antibody (Santa Cruz, WB 
= 1:500) and a goat-anti-mouse HRP antibody secondary antibody (Abcam, WB = 
1:2,500).    
Fc-γ-receptor HeLa cells were plated (5 x 104 per well) on a 24 well plate and 
incubated in 10% RPMI (Invitrogen) overnight. The cells were over-infected with C. 
burnetii NMII Phase II (WT), ∆CBU1206 or ∆dotA strains containing pJBCAT:CyaA:CvpA or 
the vector alone. The cells were incubated in 10% RPMI for 48 h. The cells were then 
harvested and re-suspended in diluted assay buffer provided with 
the Amersham cAMP Biotrak Enzymeimmunoassay kit. The assay was performed 
according to protocol RPN2251. Standards were prepared according to protocol from 0 
to 6400 fmol to generate a standard curve. The cAMP concentration of each sample was 
determined by plotting the pJB-CAT:CyaA:CvpA strains over the pJB-CAT:CyaA only 
strains.    
Statistical Methods   
All statistical analyses were performed using the Prism software by GraphPad 
(GraphPad Software, Inc., La Jolla, CA).  
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RESULTS 
Increased Sterol Accumulation on the ∆CBU1206 CCV Membrane 
Previously the lab hypothesized that CBU1206 may modify cholesterol in the CCV 
to generate sterol species beneficial for survival. Therefore, the lab generated a 
∆CBU1206 mutant utilizing SacB targeted deletion. The potential accumulation of 
cholesterol on the CCV membrane due to lack of CBU1206 was tested using the 
∆CBU1206 and the use of fillipin. This compound is a four isomeric polyene that binds to 
sterols that are not esterified such as cholesterol. It binds to cholesterol in membranes 
and forms aggregates at the ultrastructural level that can be observed with UV 
excitation around 360 nm and emission around 480 nm [43]. To visualize the cholesterol 
content on the membrane of WT and mutant infected cells were labeled with filipin. 
Since non-esterified sterols could be numerous in structure and states of esterification, I 
used a positive control: U18666A. It has been shown to inhibit lipid transport resulting in 
an accumulation of cholesterol in lysosomal structures and therefore; it was used to 
induce cholesterol accumulation on the CCV membrane [44]. The cells were incubated 
with U18666A prior to labeling with fillipin. To confirm accumulation of cholesterol on 
the mutant infected and U18666A treated cells, fillipin intensity was visualized and 
quantified using FIJI ImageJ software (Figure 4 A, B). The higher intensity of filipin in the 
mutant CCV membrane indicated increased sterol accumulation that is likely 
cholesterol.  
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Figure 4. Increased Sterol Accumulation on the ∆CBU1206 CCV Membrane. HeLa cells 
were treated with U18666A or left untreated, fixed, and labeled with filipin at 3 days 
post infection (A). Sterol accumulation is indicated by increased filipin intensity that can 
be observed in U18666A treated cells relative to DMSO controls. ∆CBU1206 infected 
cells also display increased filipin intensity relative to WT infected cells, particularly the 
DMSO controls where no cholesterol accumulation should occur. (B) Quantification of 
filipin intensity at 3 days post infection using FIJI ImageJ software. The individual CCV 
measurements from four separate experiments are shown. At least 20 CCVs were used 
in each experiment. Error bars indicate standard deviation from the mean. Statistical 
analyses used were Ordinary One-Way Anova with a Dunnett’s Multiple Comparison 
Test. **** = p < 0.0005. Arrows point to CCVs. Scale bar = 1.82 μm. 
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Method Used to Determine Protein Localization on the CCV 
The CCV acquires cellular markers such as CD63, Rab7, LAMP1, LC3, and SNARE 
proteins such as Vamp2, Vamp7, Vamp8 and Vti1b through fusion with the endocytic 
pathway and autophagosomes [45]. The endocytic pathway is composed of early 
endosomes, lysosomes, endolysosomes, and lysosomes that are continuously being 
modified or degraded. EEs undergo maturation and become acidified in the endocytic 
pathway. These mature into LEs that form larger bodies that fuse with lysosomes and 
organelles transitioning between endosomes and lysosomes. Collectively the EEs, LEs, 
endolysosomes, and lysosomes form a dynamic continuum that is continuously 
undergoing maturation and transformation events.  
The CCV membrane has been shown to be altered in response to decreasing and 
unstable CD63 and LAMP1 levels suggesting an essential role for endosomes and 
lysosomes in CCV development [46]. Through immunofluorescent microscopy visual 
confirmation of host endosomal/lysosomal marker localization to the CCV was scored 
positive or negative for localization (Figure 5A, arrow). The absence of apparent 
localization indicated by the lack of a visible outline by the marker was scored as 
negative for localization (Figure 5B, arrow). 
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Figure 5. Scoring Localization of CCV Markers on Infected CCVs. CD63 localizes to the 
CCV membrane in HeLa cells infected with (WT) mCherry C. burnetii NMII Phase II but 
does not fully localize in mCherry ∆CBU1206 infected cells at 3 dpi. Immunofluorescent 
microscopy images of WT and mutant HeLa cells stained with monoclonal anti-CD63. In 
the HeLa cell infected with WT, CD63 was seen localizing to the CCV membrane (A, 
arrow) and was scored as a positive PV (A). Host cell infected with the mutant displayed 
no localization of CD63 on CCV membrane (B, arrow) and was scored as negative (B). At 
least 20 CCVs were scored as positive or negative for the presence of CD63. Arrows 
point to CCVs. Scale bars = 2mm 
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CD63 is Present on a Decreased Number of Mutant CCVs 
Lysosomes are one of the more unique vesicle populations in the endosomal 
maturation cascade and with an acidic pH of ~4.5. CD63 was one of the host proteins 
that were used as a marker for the fusion of lysosomes with the CCV. Primarily 
associated with the membranes of intracellular vesicles, CD63 is a ubiquitous protein in 
humans and is a member of the transmembrane 4 superfamily that is commonly 
referred to as the tetraspanin family. CD63 is associated with cell-surface proteins that 
play critical roles in cell development and growth. Although CD63 is a member of the 
LAMP family that is present on lysosomes it is also found on late endosomes [47]. It has 
been shown to colocalize with cation transporter 2 (hoCT2) and small GTPase Rab4 that 
are critical in recycling of the sorting endosomes to the plasma membrane on the cell 
surface [48] [49]. In Burkholderia thailandensis tetraspanins such as CD9, CD63, and 
CD81 were shown to be involved in the regulation of multinucleated giant cell formation 
(MNGC) formation that could be induced by bacterial pathogenicity [50]. Recently it was 
demonstrated that CD63+ vesicles are not successfully eliminated from the Coxiella CCV 
without lysosomal hydrolases leading to an excess of intraluminal CD63+ vesicles. The 
excess of intraluminal vesicles resulted in an altered CCV membrane suggesting proper 
distribution of vesicles within the CCV is essential for development [46]. To understand 
the distribution and fusion of CD63 vesicles with the ∆CBU1206 infected CCVs, a time 
course of infection was conducted. The cells were visualized using immunofluorescent 
microscopy and scored by eye (Figure 6). Approximately 90% of the total WT CCVs 
displayed positive localization of CD63 beginning at 12 hours post infection while only 
about 30% of total mutant CCVS displayed positive localization. At 24, 48, and 72 hours 
post infection WT infected CCVS displayed >90% positive localization of CD63 while only 
about 50% of the total mutant CCVs acquired CD63 across all three timepoints. This data 
indicates that CD63 is acquired by a substantial group of WT CCV population beginning 
at 24 hpi. This is in stark contrast with the mutant CCVS where 70% of mutant CCVs 
failed to acquire CD63 or does not fuse with CD63+ vesicles until 48 hours after 
infection. The time points 24, 48, and 72 hpi maybe critical stages in CCV development 
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as all WT CCVs are positive for the presence of CD63. The lack of CD63 on the mutant 
CCV membranes may indicate delayed vesicle fusion or a defective membrane that does 
not allow for proper fusion with late endosome/lysosome vesicles. 
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Figure 6. CD63 is Present on a Decreased Number of Mutant CCVs. CD63 localizes to 
the CCV membrane of HeLa cells infected with (WT) mCherry C. burnetii NMII Phase II. 
At 24, 48, and 72 hpi >90% of WT CCVs were positive for CD63. At 24 hpi, approximately 
30% of mutant CCVs were positive. At 48 and 72 hpi about 50% of the mutant CCVs 
were CD63 positive. Results are shown for three individual experiments. Error bars 
represent the standard error of the mean. Statistical analyses were Multiple t tests and 
Holm-Sidak Method multiple comparison test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; 
**** =p < 0.0005 
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LAMP1 is Present on Mutant CCVs 
LAMP1 was the primary host protein used as a marker for the fusion of 
lysosomes with the CCV. Lysosomal Associated Membrane Protein 1 or LAMP1 is a 
protein in the family of membrane glycoproteins. LAMP1 is a heavily N-glycoslyated 
integral protein on the lysosomal membrane that is trafficked from the trans-Golgi 
network to the lysosomes [51]. It has been heavily associated with maintaining the 
lysosomal pH, integrity and catabolism. Most intracellular pathogens such as 
Mycobacterium, Salmonella, Legionella and Toxoplasma actively manipulate the host 
endocytic pathway to avoid fusion with lysosomes, however, Salmonella-containing 
phagosomes have been shown to acquire LAMP1 [52] [53]. S. typhimurium has been 
shown to recruit LAMP1 by fusing with Golgi-derived vesicles through a SipC-Syntaxin6-
mediated event surpassing the need to fuse with lysosomes [53]. Neisseria has been 
shown to promote the degradation of LAMP1 through the Neisseria type 2 IgA1 
protease allowing for its intracellular growth and pathogenesis [54]. A group looking at 
internalization routes of C. burnetii and the effects of vesicular trafficking on that 
process concluded that lack of LAMP1 and LAMP2 results in increased fusion with the 
endosomes and lysosomes but does not result in PV enlargement [55]. Another study 
claimed somewhat contradictory findings where fusion events of the CCV membranes 
were decreased due to lower levels of LAMP1 resulting in smaller CCVs [46]. Regardless 
of conclusions regarding fusion events both studies conclude that LAMPs play an 
essential role in the expansion of the CCV. This was further supported by CCV lysates 
that were significantly enriched for the presence of LAMP1 and LAMP2 relative to whole 
cell lysates possibly indicating crucial roles for the CCV expansion and maintenance [56]. 
While the effect of LAMP1 has been somewhat characterized in the WT CCV, I hoped to 
understand CCV and LAMP1 interactions through the ∆CBU1206 infected CCV. Infected 
cells were visualized using immunofluorescent microscopy and scored by eye (Figure 7). 
Unlike the delayed acquiring displayed with other markers, the mutant displayed a 
different pattern of localization that is similar to WT. At 24 hpi almost all (>95%) the WT 
CCVs scored positive for the presence of LAMP1 and remained positive through 48 and 
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72 hpi. Around 70% of the total mutant CCVs also scored positive for the presence of 
LAMP1 on the CCV membrane and 100% of the mutant CCVs were positive for LAMP1 at 
72 hpi. The mutant CCVs become increasingly positive for the presence of LAMP1 unlike 
with other CCV markers but still displays delayed recruitment relative to WT. The 
mature CCV membrane has been shown to acquire all the lysosomal glycoproteins 
LAMP-1, LAMP-2 and LAMP-3 while decreased levels of LAMP1 causes smaller CCVs [13, 
55]. These findings might implicate a critical role of LAMP1 in CCV development and 
formation from early infection to late infection both in WT and mutant CCVs.  
  
 32 
 
  
 33 
Figure 7. LAMP1 is Present on Mutant CCVs. LAMP1 localizes to the CCV membrane of 
HeLa cells infected with (WT) mCherry C. burnetii NMII Phase II and mCherry ∆CBU1206 
infected cells. At 24, 48 and 72 hpi >95% of the WT CCVs and >60% of the mutant CCVs 
were positive for LAMP1. At 72 hpi 100% of both WT and mutant CCVs were positive for 
LAMP1. At least 20 CCVs were scored as positive or negative for the presence of LAMP1. 
Results are shown for three individual experiments. Error bars represent the standard 
error of the mean. Statistical analyses were Multiple t tests and Holm-Sidak Method 
multiple comparison test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; **** =p < 0.0005.  
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Rab7 is Present on a Decreased Number of Mutant CCVs 
Late endosomes contain distinct late endocytic cargo and a pH of ~5.0. They 
deliver these unique components to the CCV post fusion. In order to better understand 
late endosome recruitment to the CCV in the absence of CBU1206, I used Rab7, ORP1L, 
and RILP as late endosomal markers. The RAB7A gene encodes the Ras-related protein 
Rab-7a (Rab7) that is a small GTPase of the Rab family. Rab7 can be found co-localizing 
with ORP1L on late endosomes and lysosomes [57]. Rab7 and its effector (Rab-
interacting lysosomal protein) RILP primarily localizes to late endosomes and directs the 
transport of early endosomes to the Trans Golgi Network (TGN) while playing a crucial 
role in endosomal trafficking [58]. Its role in regulating endosomal sorting, lysosomal 
biogenesis, and phagocytosis makes it relevant in the context of intracellular pathogen 
infection [59]. Rab7 and its partner GTPases have been characterized as key regulators 
in the phagosome maturation process of several intracellular pathogens. 
Mycobacterium tuberculosis phagosome maturation is arrested in early stages through 
selective exclusion of Rab7 effectively blocking fusion with late endosomes. This allows 
the Mycobacterium-containing phagosomes to escape degradation and thrive in its 
intracellular niche [60]. Salmonella enterica resides in Salmonella-containing vacuoles 
that have been shown to lose integrity when Rab7 is overexpressed in cells [61]. CCV 
fusion with the late endosomes requires Rab7 and the CCV has been shown to have 
substantial labeling of Rab7 at 48 hpi [62]. Expression of dominant-negative Rab7 
mutant forms during infection has altered both CCV formation and intracellular 
replication [62] [63]. Considering the wide array of functions Rab7 has from endosomal 
sorting to phagocytosis, it was important to investigate mutant recruitment of Rab7 
containing vesicles. Transfected cells were infected, visualized using immunofluorescent 
microscopy, and scored by eye (Figure 8). Approximately 50% of the total WT CCVs 
counted were positive for the presence of Rab7 and about 90% of CCVs were positive at 
48 hpi. Although all the WT CCVs were positive for the presence of Rab7 on the 
membrane only about 30% of mutant CCVs were positive for Rab7. Approximately 70% 
of the mutant CCVs fail to acquire Rab7 even at 72 hpi when the CCV is expected to be 
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stabilized. Lack of Rab7 on the mutant CCVs was observed across all time points relative 
to WT and may indicate that the mutant is unable to properly regulate late endosome 
and lysosome vesicle fusion events. Although, Rab7 is only slowly acquired relative to 
lysosomal markers (LAMP1 and CD63) it has been shown to affect CCV formation and 
replication, therefore, Rab7 positive vesicle fusion events maybe more minutely 
regulated by Coxiella.  
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Figure 8. Rab7 is Present on a Decreased Number of Mutant CCVs. Rab7 localizes to the 
CCV membrane of HeLa cells infected with (WT) mCherry C. burnetii NMII Phase II 
steadily over 4, 12, 24, 48, and 72 hpi. CCVs infected with mCherry ∆CBU1206 did not 
readily acquire Rab7. At 48 and 72 hpi, >90% of WT CCVs and <50% of mutant CCVs 
were positive for Rab7. At least 20 CCVs were scored as positive or negative for the 
presence of Rab7. Results are shown for three individual experiments. Error bars 
represent the standard error of the mean. Statistical analyses were Multiple t tests and 
Holm-Sidak Method multiple comparison test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; 
**** =p < 0.0005.  
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ORP1L is Present on a Decreased Number of Mutant CCVs  
Oxysterol-binding protein-related protein 1 or ORP1L is a member of the human 
oxysterol-binding protein (OSBP) family. ORP1L is primarily found on late endosomes 
and lysosomes [57]. It modulates the cholesterol levels on late endosomes through 
conformational changes dictated by high and low levels of cholesterol. When 
cholesterol levels are high, ORP1L binds to cholesterol through its C-terminal oxysterol-
binding protein (OSBP)-related domain (ORD) and adopts a confirmation to enable the 
N-terminal ankyrin repeat domain (ARD) to interact with the Rab7-RILP complex 
positioning late endosomes [64]. When cholesterol levels are low, cholesterol does not 
bind the ORD domain exposing the FFAT motif adjacent to it. The FFAT motif is detected 
by the endoplasmic reticulum protein (ER) VAP forming ER and late endosome 
membrane contact sites [65]. Previous work from the lab suggests that ORP1L localizes 
to the WT CCV in a Dot/Icm type IV secretion system (T4SS) dependent manner. ORP1L 
binds the CCV membrane proteins via N-terminal ankyrin repeats and is involved in CCV 
and ER interactions. Infection of cells depleted of ORP1L using siRNA resulted in smaller 
PVs at 6 days post infection. Furthermore, the recruitment of RILP and Rab7 to the CCVs 
in both normal and ORP1L-depleted cells indicated that diminished CCV size was not due 
ORP1L interacting partners [45]. ORP1L has been shown to have an essential role in the 
CCV size and CCV interactions with the ER, therefore; it is likely that ORP1L has a role in 
altering or maintaining the CCV membrane. Considering its close association to CCV 
membrane function, ORP1L localization was investigated in the context of ∆CBU1206. 
ORP1L localization to WT and mutant was observed. Infected cells were visualized using 
immunofluorescent microscopy and scored by eye (Figure 9). Corresponding with 
previous observations in the lab, ORP1L was rapidly acquired by the WT CCVs beginning 
12 hpi with >80% of CCVs positive for ORP1L at 24 hpi [45]. More than 95% of WT CCVs 
acquired ORP1L at 48 hpi and all CCVs were positive at 72 hpi. Interestingly, the mutant 
CCVs also display and increase of ORP1L recruitment after 12 hpi but was not 
comparable to the WT increase. Only >15% of mutant CCVs were positive for the 
recruitment of ORP1L while >75% of WT showed recruitment of ORP1L. Although the 
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number of ORP1L-positive CCVs increased over time, at 72 hpi less than 60% of total 
CCVS were positive for the presence of ORP1L on the CCV membrane. Considering the 
role of ORP1L in CCV membrane function, delayed ORP1L recruitment maybe indicative 
of delayed CCV development and CCV interactions with the ER.  
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Figure 9. ORP1L is Present on a Decreased Number of Mutant CCVs. ORP1L localizes to 
the CCV membrane of HeLa cells infected with (WT) mCherry rapidly following 12 hpi. 
CCVs infected with mCherry ∆CBU1206 acquired ORP1L in a delayed manner relative to 
WT. At 24 hpi, >75% of WT CCVs and <30% of mutant CCVs were positive for ORP1L. At 
72 hpi, 100% of the WT CCVs and approximately 50% of the mutant CCVs acquired 
ORP1L. At least 20 CCVs were scored as positive or negative for the presence of ORP1L. 
Results are shown for three individual experiments. Error bars represent the standard 
error of the mean. Statistical analyses were Multiple t tests and Holm-Sidak Method 
multiple comparison test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; **** =p < 0.0005.  
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RILP is Present on a Decreased Number of Mutant CCVs  
The 45 kDa protein binding to Rab7 at its C-terminus is the Rab-interacting 
lysosomal protein (RILP) [66]. It localizes to late endosomes and lysosomes acting as a 
downstream effector of Rab7 controlling the transport of endocytic compartments. RILP 
interacts with the Vps22 and Vsp36 subunits of the endosomal sorting complex (ESCRT- 
II) that are important for the biogenesis multivesicular endosomes (MVEs) that are the 
equivalent of late endosomes [67]. More relevant in the context of this study is the 
binding of the RILP in the ORP1L-Rab7-RILP tripartite complex that regulates late 
endosome positioning [64]. The complex is formed when RILP binds to the switch 
regions of Rab7 to arrest it in the active state. This is followed by the ORP1L interactions 
with the ER VAP proteins and binding to the Rab7-RILP complex thus forming the 
tripartite complex [68]. Further, recruitment of the dynein-dynactin motor occurs when 
RILP associates with the p150(Glued) subunit of the dynein motor effectively controlling 
the microtubule driven minus-end transport of late endosomes, lysosomes, and 
melanosomes [68, 69]. The Salmonella typhimurium vacuoles mature in a process 
similar to that of Coxiella in which it acquires Rab5 and Rab7 sequentially but do not 
fuse with lysosomes. Instead the vacuoles are relocated towards the cell periphery 
through a filamentous network due to recruitment of Rab7 by RILP [70]. Another 
intracellular pathogen Brucella abortus also resides in membrane-bound acidic 
compartment termed Brucella-containing vacuole (BCV). BCVs have been shown to 
acquire LAMP-1 and other late endocytic markers such as Rab7 and RILP indicating that 
the BCV development involves the recruitment of late endosome/lysosome components 
[71]. Neisseria gonorrhoeae reside in phagosomes inside host cells where maturation is 
arrested prior to acquiring Rab7 or RILP allowing the bacteria to thrive within the 
phagosome [72]. During Coxiella infection overexpression of RILP led to the formation of 
non-replicating CCVs suggesting that RILP maybe essential for CCV biogenesis [73]. Both 
RILP and Rab7 localize to the CCVs in ORP1L – depleted cells that resulted in smaller 
CCVs thus indicating that the RILP-Rab7 complex could be recruited independent of 
ORP1L and that the RILP-Rab7 complex cannot compensate for the role of ORP1L in CCV 
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size [45]. In order to better understand the role of RILP and the dynein-dynactin 
complex during WT and mutant Coxiella infection, a time course of the infection was 
conducted. RILP localization was visualized using immunofluorescent microscopy and 
scored by eye (Figure 10). Acquiring of the RILP across the 0 hpi to 72 hpi was delayed in 
the mutant CCVs relative to WT CCVs. Like the rapid recruitment of ORP1L following 12 
hpi, RILP also displayed enhanced recruitment after 12 hpi in WT CCVs. Although mutant 
CCVs also displayed increased recruitment of RILP following 12 hpi, there was no 
increase in the number of RILP-positive CCVs between 24 hpi and 48 hpi. In contrast, 
>80% of WT CCVs were positive for RILP at 48 hpi and all WT CCVs were positive at 72 
hpi. About half of the mutant CCVs do not acquire RILP by 72 hpi possibly indicating 
defective recruitment of RILP positive vesicles or aberrant interactions with the 
tripartite complex.  
  
 44 
 
  
 45 
Figure 10. RILP is Present on a Decreased Number of Mutant CCVs. RILP localizes to the 
CCV membrane of HeLa cells infected with (WT) mCherry C. burneti NMII Phase II. CCVs 
infected with mCherry ∆CBU1206 displayed delayed recruitment of RILP. At 48 hpi, 
>80% of WT CCVs and <30% of mutant CCVs were positive for RILP. At 72 hpi, 
approximately 50% of mutant CCVs and 100% of the WT CCVs acquired RILP. At least 20 
CCVs were scored as positive or negative for the presence of RILP. Results are shown for 
three individual experiments. Error bars represent the standard error of the mean. 
Statistical analyses were Multiple t tests and Holm-Sidak Method multiple comparison 
test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; **** =p < 0.0005.  
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LC3 is Present on a Decreased Number of Mutant CCVs  
Autophagosomes are suspected to have a pH ~ 6.0 and carry a broad array of 
cellular material to be targeted for autophagy. In this work, LC3 was used as the marker 
for CCV fusion with autophagosomes. Autophagy is a predominant response to stresses 
such as starvation and infection. Microtubule-associated proteins 1A/1B light chain 3B 
(LC3) functions in autophagy substrate selection and is a critical protein in the 
autophagy pathway. Hence, LC3 is a commonly used marker of autophagosomes. 
Intracellular homeostasis is closely tied to autophagy along with antigen presentation, 
infection, and cell death. LC3 containing autophagosomes are formed during the 
autophagy and fuse with lysosomes to form autolysosomes that degrade cellular 
components [74]. LC3 is also referred to as ATG8 and is one of the autophagy-related 
(atg) genes that regulate the autophagy pathway [75]. Several intracellular pathogens 
have been shown to subvert or manipulate the host autophagy pathway to acquire 
nutrients or xenophagy. Listeria monocytogenes once internalized survive inside 
macrophages in Listeria-containing phagosomes (SLAPs) that contain LC3 [76] possibly 
indicating that LC3 may be recruited for SLAP formation. In Coxiella, impairing host 
autophagy has resulted in a decrease in the overall number of CCVs and therefore, could 
be involved in the overall maintenance of the CCV [77]. LC3 has been shown to be 
acquired by the CCV as early as 5 min after infection and dependent on C. burnetii 
protein synthesis as no LC3 processing was visible in cell treated with chloramphenicol 
[78]. Furthermore, a screen of C. burnetii NMII transposon insertion mutants included 
those that had defects in effector proteins such as Cig57, CoxCC8, Cig2 and CBU1754. 
The authors reported a multi-vacuolar phenotype in mutants with transposon insertions 
in the Cig protein encoding gene. These vacuoles were also lacking LC3 while the WT 
CCVs displayed significant amounts of LC3 on vacuole [79]. Therefore, it is possible that 
the C. burnetii effector proteins secreted through the T4SS could be influencing the 
fusogenicity of Coxiella phagosomes and their ability to homotypically fuse with each 
other. In order to clarify the proper recruitment of LC3 to the mutant CCV and to 
understand the effects of autophagy following recruitment, LC3 localization on the WT 
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and mutant CCVs were visualized at 0, 4, 12, 24, 48, and 72 hpi. Cells were visualized 
using immunofluorescent microscopy and scored by eye (Figure 11). Interestingly, both 
WT and mutant CCVs display a pattern of localization similar to that of RILP localization. 
A dramatic increase in the localization of LC3 to WT CCVs was not observed at 4 hpi 
inconsistent with previous observations where LC3 localized 5 mins post infection [78]. 
This is most likely because the method of LC3 detection in these experiments is not 
sufficiently sensitive to detect the presence of small levels of accumulating LC3. By 48 
hpi >50% of WT CCVs are positive for the presence of LC3 and 10% of the mutant CCVs 
were positive for LC3 recruitment. Mutant recruitment of LC3 seems to compensate 
somewhat at 72 hpi when the number of LC3-positive CCVs increase to approximately 
40%. The 60% of mutant CCVs that are not positive for LC3 at 72 hpi might acquire the 
autophagy protein later in infection. The lack of it is indicative of defective 
autophagosome fusion or aberrant interactions of the mutant with the host autophagy 
pathway.  
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Figure 11. LC3 is Present on a Decreased Number of Mutant CCVs. LC3 localizes to the 
CCV membrane of (WT) mCherry C. burnetti NMII Phase II infected HeLa cells. CCVs 
infected with mCherry ∆CBU1206 displayed delayed and minimal recruitment of LC3. At 
48 hpi, <30% of mutant CCVs and >60% of WT CCVs were positive for LC3. At 72 hpi, 
approximately 40% of mutant CCVs and 100% of WT CCVs were positive for LC3. At least 
20 CCVs were scored as positive or negative for the presence of LC3. Results are shown 
for three individual experiments. Error bars represent the standard error of the mean. 
Statistical analyses were Multiple t tests and Holm-Sidak Method multiple comparison 
test. * = p < 0.5; ** = p < 0.05; *** = p < 0.005; **** =p < 0.0005.  
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∆CBU1206 Possesses a Functional Type IV Secretion System  
Often referred to as “adapted conjugation systems” Type IV Secretion Systems 
(T4SS) have homology to plasmid transfer systems. The Dot/Icm T4SS complex is 
possessed by intracellular pathogens such as Legionella, Brucella, Bartonella, and 
Anaplasma [80]. It is also possessed by Legionella related class member Coxiella burnetii 
[81]. The C. burnetii genome harbors 24 of the 26 L. pneumophila Dot/Icm proteins 
except for the DotV and IcmR proteins [82]. While the L. pneumophila T4SS has been 
shown to secrete 330 effectors that represents more 10% of the its whole genome, 
Coxiella secretes approximately 133 effectors that account for 6% of its genome [81]. 
These effectors have been demonstrated to influence a variety of CCV biogenesis events 
including expansion, nutrient acquisition, apoptosis inhibition, and manipulating host 
vesicle trafficking [83]. Effectors thought to influence host vesicle trafficking include 
CvpA that interacts with the clathrin-adaptor complex AP2 and is trafficked through the 
host endocytic recycling network possibly influencing host vesicle regulation [81, 84]. 
Effector proteins have also been shown to modulate the host apoptosis response to 
Coxiella infection. These include AnkG, CaeA, CaeB, and CBU1314 that block host 
mediated apoptosis through various mechanisms [81 {Weber, 2016 #188 {Weber, 2016 
#188].  AnkG is a C. burnetii effector from the ankyrin repeat (Ank) family and it  acts by 
binding to the host protein p32 to block pathogen-induced apoptosis [85]. CaeA seems 
to act on the apoptosis pathway by acting downstream of the cell death cascade and 
preventing the cleavage of caspase-7 that is responsible for execution of apoptosis. 
CaeB has been shown to target the mitochondrial outer membrane but the exact 
mechanism is unclear [86]. CBU1314 targets host driven apoptosis by associating with 
host chromatin to modulate the host transcription [87]. Further, mutants of the 
effectors CvpB, CvpC, CvpD, and CvpE were shown to have significant defects in 
intracellular growth and PV development with CvpB producing significantly smaller CCVs 
[88]. Unpublished data from the lab has also shown significantly smaller ∆CBU1206 CCVs 
compared to WT. These observations and existing data on effector protein functions 
raised the possibility that the mutant phenotypes could be due to the lack of effector 
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proteins. Taking into consideration the substantial role effector proteins have during 
infection, it was critical to investigate mutant effector protein secretion capabilities. The 
translocation of effector proteins through the bacterial secretion systems has been 
monitored through Adenylate Cyclase Reporter Assays. 
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Figure 12. The Adenylate Cyclase Reporter Converts ATP to cAMP. CyaA:CvpA strains 
produce mRNA that gets translated into protein inside the bacterium and gets 
translocated across the Coxiella Type 4 Secretion System. The calmodulin-dependent 
adenylate-cyclase domain of the adenylate cyclase (CyaA) reporter fused to CvpA 
encounters calmodulin (CaM) in the host cytosol. Upon binding of CaM with the ACD 
domain the adenylate cyclase converts cytosolic adenosine triphosphate (ATP) into 
cyclic adenosine monophosphate (cAMP).  
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For C. burnetii CyaA assays, transformants were constructed using  pJB-CAT:BlaM 
and pJB-CAT:CyaA plasmid that were used to fuse BlaM and CyaA to the N terminus of C. 
burnetii effector genes [89]. We generated six different strains to approach mutant 
effector protein secretion as follows : WT:CyaA, ∆CBU1206:CyaA, ∆dotA:CyaA, 
WT:CyaA:CvpA, ∆CBU1206:CyaA:CvpA, and ∆dotA:CyaA:CvpA. The strains were fused 
with the adenylate cyclase or both the cyclase and CvpA that has been shown to 
delivered to the host-cell cytosol in a T4SS dependent manner [90]. The CyaA-only 
proteins should not be translocated to the cytoplasm as they are not fused to a known 
effector protein that is secreted. In contrast, the CvpA:CyaA proteins are translocated to 
the cytoplasm to produce cAMP, unless the T4SS is dysfunctional (Figure 12). The cAMP 
concentrations of the CyaA only strains were plotted over the CyaA + CvpA strains to 
generate fold changes in cAMP concentration for WT, ∆CBU1206, and ∆dotA (Figure 13). 
WT displayed the highest levels fold change of cAMP while ∆dotA displayed the lowest 
levels of fold change in cAMP concentration. The intermediate levels of cAMP fold 
change indicate that the ∆CBU1206 does possess a functional Type 4 Secretion System 
even if it may not be as efficient as the WT T4SS.  
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Figure 13. ∆CBU1206 Possesses a Functional Type IV Secretion System. ∆CBU1206 has 
a functional Type 4 Secretion System. The fold change of intracellular cAMP levels was 
significant between ∆CBU1206 and ∆dotA mutant. The fold change in WT cAMP levels 
was higher than both ∆dotA and ∆CBU1206 KO. Results are shown for six individual 
experiments. Error bars represent the standard deviation from the mean. Statistical 
analyses were Ordinary one-way Anova and Tukey’s multiple comparison test. * = p < 
0.5; ** = p < 0.05; *** = p < 0.005; **** =p < 0.0005.  
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DISCUSSION 
In this work, I examined the localization of markers for host endosomes and 
lysosomes to the ∆CBU1206 CCV. This is an important aspect in the life of an 
intracellular pathogen because of the way these processes disrupt eukaryotic pathways. 
Since intracellular bacteria manipulate host cell vesicular transport pathways using 
diverse methods, it was important to investigate the localization of host proteins to gain 
a deeper understanding of Coxiella-host interactions.  
Previous work from the lab demonstrated that C. burnetii inhibits endosomal 
maturation to regulate fusion with active lysosomes and maintain the ideal CCV pH (~ 
5.2) [24]. This work also showed that increasing the number of proteolytically active 
lysosomes significantly stagger Coxiella growth and CCV development. However, even in 
the context of C. burnetii ∆cvp mutants, where the they lacked the Coxiella vacuolar 
proteins B, C, D and E individually, all mutants were positive for LAMP1 [88]. These 
mutants were shown to have defects in CCV development and intracellular replication 
similar to the unpublished findings related to ∆CBU1206. These findings are consistent 
with the data presented in this work where the mutant seems to preferentially fuse with 
lysosomes but is defective in CCV development. Observing the time course of LAMP1 
localization to the mutant CCV, the pattern of localization is highly similar to WT where 
the marker is acquired rapidly and starting 4 hpi. Unlike the late endosomal markers 
LAMP1 was readily acquired by the mutant and might suggest that the ∆CBU1206 CCV 
selectively fuses lysosomes and acidifies the vacuole. The selective fusion observed 
might lead to acidification of the vacuole and contribute to the growth defect observed 
(Figure 5B).  
A recent study demonstrated that the CD63-positive intraluminal vesicles must 
be eliminated through lysosomal hydrolases for normal CCV membrane organization 
[88]. So, it can be predicted that CD63 is involved in a series of complex cellular events 
that may not be unilateral. According to our data, it appears that CD63 is recruited by 
the mutant beginning at 4 hpi and continues to be recruited at a steady pace until 
approximately 50% of the CCVs are positive for the marker at 72 hpi (Figure 6). In the 
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WT population CD63 localizes to 100% of the population past 12 hpi similar to the 
localization profile of the lysosomal marker LAMP1. It is unclear whether a percentage 
of the mutant population fails to recruit the CD63 positive vesicles altogether or fails to 
retain them. It may also be possible that WT fuses with a distinct vesicle population 
positive for both LAMP1 and CD63 but the mutant fails to acquire these distinct vesicles. 
Taking into account previous work from above, it seems that the C. burnetii carefully 
regulates the recruitment and elimination of CD63 vesicles through lysosomal 
hydrolases. So, it is also possible that the CD63 observed on the 100% of the WT CCVs at 
12, 24, 48, and 72 hpi are CD63 vesicles that were retained while the rest were 
eliminated. This indicates a defect in the recruitment or elimination of CD63 vesicles by 
the mutant. 
Cholesterol has been directly associated with the pathogenesis of numerous 
bacteria such as Mycoplasma, Chlamydia, Anaplasma, Helicobacter and Borrelia [91] 
[36]. They can manipulate the cholesterol trafficking pathways to access nutrients and 
membrane components that can ease vacuole formation. In B. burgdorferi this is 
thought to occur when there is direct contact between the bacteria and mammalian 
cells through outer membrane vesicles. The transfer of the outer membrane vesicles to 
host cells was assessed through the transfer of labeled cholesterol that have been 
predicted to form lipid rafts [91]. In contrast, cholesterol seems to play a negative role in 
vacuole formation of Coxiella burnetii where increasing CCV cholesterol acidifies the 
CCV leading to bacterial death [42]. Accumulation of cholesterol on the ∆CBU1206 CCV 
membrane was shown (Figure 4A) and is possibly affecting the fusogenic properties of 
the vacuole. Furthermore, accumulation of cholesterol on late endosomes also results in 
the inhibition of intra-endosomal membrane dynamics altering protein and lipid 
trafficking [8]. I discovered cholesterol accumulation on the CCV and pursued this 
further by observing late endosome marker recruitment. Late endosomal markers Rab7, 
RILP, and ORP1L were scored on the CCV membrane.  
The late endosome unique marker Rab7 was only present in 30% of the mutant 
CCVs at 72 hpi (Figure 8). This was surprising because Rab GTPases have been 
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established as a prominent method for intracellular pathogens to manipulate the 
phagosome to their advantage [88]. Although the WT slowly but steadily acquires the 
Rab7, the mutant lags and shows no increase in acquiring the marker starting 12 hpi. 
During phagosome formation Rab7 mediates fusion of phagosomes with late 
endosomes and recruits RILP in addition to the forming the tripartite complex (ORP1L-
Rab7-RILP) [92]. The Rab7 effector RILP had a localization profile in WT CCVs similar to 
that of Rab7 where both markers localize to an increasing percentage of the CCV 
population from 12 hpi to 72 hpi (Figure 10). This might indicate defective phagosome 
maturation caused by defective recruitment of the dynein-dynactin motor complex 
since RILP has been shown to recruit this complex [68]. This directly impacts late 
endosome maturation, positioning, and other regulatory mechanisms that may be 
involved. The close association of Rab7, RILP and ORP1L might explain the similar 
localization patterns in WT CCVs. In the mutant CCVs Rab7 and RILP localization was 
dissimilar. Approximately 50% of the mutant population was positive for RILP while less 
than 40% of the population was positive for Rab7. Less than 50% of mutant CCVs 
acquiring Rab7 and RILP could be due to a critical flaw in the fusion of late endosomes 
by the mutant. If cholesterol is involved in CCV-host signaling this could indicate 
defective signaling related to the Rab GTPases as they are critical for endosomal 
maturation. Endolysosome vesicle maturation and differentiation could be defective in 
mutant infected cells.  
The late endosomal marker ORP1L is present in less than 50% of the mutant and 
100% of the WT CCVs at 72 hpi. ORP1L has been shown to bind the WT CCV membrane 
through N-terminal ankyrin repeats and simultaneously associate the CCV and ER [45]. 
Interestingly, the WT CCVs begin to exhibit ORP1L recruitment 12 hpi (Figure 9). It may 
be important to recruit ORP1L positive vesicles beginning at early times of infection 
considering its demonstrated importance in CCV-ER membrane contact sites and its role 
in endosomal maturation. This increase at 12 hpi was not observed in the mutant CCV 
population. Considering the effects of ORP1L depletion on CCV size, it is possible that 
the delay in acquiring late endosomal markers is due to lack of ORP1L at early stages of 
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mutant phagosome formation [45]. Further experimentation is needed to investigate 
Rab7-ORP1-RILP interactions and localization to the CCV. These observations suggest 
that approximately half of the mutant population is not acquiring endosomal pH and 
cargo possibly contributing to defective mutant CCV maturation.  
Although, the role of LC3 has not been directly linked to CCV formation or C. 
burnetii replication, it is clear that autophagosomes fuse with the CCV. LC3 accumulates 
on the CCV as it expands and Coxiella replicates inside the CCV indicating fusion with 
autophagosomes [93]. I observed LC3 localization to the WT and mutant CCVs and 
observed a significant difference at 72 hpi only. In the WT CCVs, it appears that LC3 
accumulates on the CCV as it expands based on the steady linear increase of the WT 
graph. This is in direct contrast with the mutant CCVs where <20% of the population was 
positive at 24 hpi and <40% was positive at 72 hpi. Our data suggests that the mutant is 
defectively fusing with autophagosomes and this may have larger implications in its 
ability to manipulate host cell autophagy.  
A functional T4SS is essential for Coxiella to survive in a host cell past 2 dpi. This 
secretion system secretes effector proteins that modulate host cell processes and 
maintains the CCV. A persistent query at the heart of this study is whether the 
phenotypes observed with the CCV markers are due to a decreased number of effector 
proteins. I observed that the cAMP output of the ∆CBU1206 was significantly higher 
than that of the ∆dotA mutant that is unable to secrete effectors (Figure 13). Yet, the 
amount of cAMP produced by the ∆CBU1206 was approximately one fold less than WT 
indicating that although effector secretion occurs, it is not at endogenous levels. The 
limited effector secretion observed could contribute to the defective 
endosomal/lysosomal localization displayed by the mutant, but it is not the only 
causative mechanism. This reduction in the overall concentration of Coxiella effectors 
due to lack of CBU1206 might suggest that CBU1206 functions are essential for host cell 
manipulation and pathogenesis.  
Fusion of the Coxiella containing vacuole with the host endocytic pathway is 
critical for the bacterium’s survival and maintenance of the CCV as a replication-
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permissive phagolysosome. This study examined the effects of host 
endosome/lysosome recruitment to the CCV in the absence of the putative sterol 
modifying enzyme CBU1206. The mutant defectively acquires the endolysosomal 
markers Rab7, ORP1L, RILP, and CD63. This effect was also observed with the 
autophagosomal marker LC3 indicating a defect in autophagosome fusion. In contrast, 
the mutant rapidly acquires the lysosomal marker LAMP1. In the absence of the 
CBU1206, there seems to be selective fusion with acidic vesicles such as lysosomes but 
minimal fusion with more alkaline vesicles such as late endosomes. Bacteriolytic effects 
have been observed during CCV cholesterol accumulation and CCV acidification [42]. 
Both sterol accumulation and CCV acidification might contribute to the defective CCV 
formation and fusion with host proteins.  
A more comprehensive understanding of host protein localization to the 
developing CCV is needed. Experiments in transfected host cells visualized through live 
confocal microscopy could help discern whether host proteins accumulate or associate 
with the CCV membrane in a transient manner. Our observations of altered lipid content 
on the ∆CBU1206 CCV membrane and this mutant being hypersensitive to host 
cholesterol (Figure 5) suggests this mutant can provide definitive conclusions in relation 
to the effects of sterol deregulation. Therefore, it maybe beneficial to observe the 
lumenal content of the mutant CCV for differences in vesicle fusion in response to 
increasing levels of cholesterol. Although Coxiella virulence is not directly attributed to 
CCV size or intracellular replication; altered lipid content in the CCV membrane might 
impact the CCV fusogenicity and viability in a host cell. Investigating WT and ∆CBU1206 
CCV formation and fusion events in a mouse model could provide insights into the 
impact of sterol deregulation on disease progression. Overall, these experiments would 
contribute to our knowledge on the topic of host and CCV cholesterol regulation by 
Coxiella burnetii. In this manner, the mechanisms of CCV biogenesis at the expense of 
host cell manipulation would be revealed.  
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